RSV Monoclonal Antibody Products Show 90% Effectiveness in Preventing Hospitalization for Children and Infants During RSV Season

New Zealand
Beyfortus was approved by the Food and Drug Administration last summer for use in any child born during RSV season or who was under 8 months of age when RSV season began.
Children at high risk of becoming severely ill if they contract RSV are also eligible to get it in their second RSV season if they are between the ages of 8 months and 19 months. The data from the first season it was in use showed that Beyfortus was 90% effective at preventing little children from being hospitalized with RSV.
Nirsevimab effectiveness was also found to be 90% against RSV-associated hospitalization in infants in their first RSV season. The median time from receipt of nirsevimab to symptom onset was start highlight45 days (IQR = 19–76).
RSV, or respiratory syncytial virus, is a common cause of mild cold-like symptoms such as runny nose, cough and fever. It can also be more serious for infants and older adults.
RSV Monoclonal Antibody Products Show 90% Effectiveness in Preventing Hospitalization for Children and Infants During RSV Season

RSV, or respiratory syncytial virus, is a common cause of mild cold-like symptoms such as runny nose, cough and fever. It can also be more serious for infants and older adults. In the 2024-25 season, RSV monoclonal antibody products Beyfortus was approved by the Food and Drug Administration last summer for use in any child born during RSV season or who was under 8 months of age when RSV season began. Children at high risk of becoming severely ill if they contract RSV are also eligible to get it in their second RSV season if they are between the ages of 8 months and 19 months. The data from the first season it was in use showed that Beyfortus was 90% effective at preventing little children from being hospitalized with RSV, according to new data from the Centers for Disease Control and Prevention (CDC). Nirsevimab effectiveness was also found to be 90% against RSV-associated hospitalization in infants in their first RSV season. The median time from receipt of nirsevimab to symptom onset was start highlight45 days (IQR = 19–76). It's important for parents and caregivers to be aware of the symptoms of RSV, which include a runny nose, coughing, sore throat, fever or chills. If you suspect your child may have RSV or if they are experiencing severe symptoms such as difficulty breathing or bluish skin tone it is important to seek medical attention immediately.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

90%

Doubts
  • It's not clear if the effectiveness of these antibody products will hold up over multiple seasons.

Sources

85%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Early Estimate of Nirsevimab Effectiveness for Prevention ...

Centers for Disease Control and Prevention (CDC) Thursday, 07 March 2024 00:00
  • Unique Points
    • Nirsevimab effectiveness was 90% against RSV-associated hospitalization in infants in their first RSV season.
    • RSV is the leading cause of hospitalization among U.S. infants.
  • Accuracy
    • RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC
    • Only about 41 percent of women with an infant under 8 months of age reported that their child had gotten the shot as of January.
    • The elderly are more likely to be vaccinated against RSV than women. Those who were vaccinated had higher levels of concern about the disease, believed they were at greater risk for getting it, believed that vaccines were safe and important, and had higher levels of trust in health institutions.
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (85%)
    The article contains an appeal to authority fallacy by citing the CDC as a source of information. The author also uses inflammatory rhetoric when stating that RSV is the leading cause of hospitalization among infants in the United States.
    • > In August 2023, CDC recommended nirsevimab, a long-acting monoclonal antibody, to protect infants aged <8 months against RSV-associated lower respiratory tract infection in their first RSV season.
    • The author uses inflammatory rhetoric when stating that RSV is the leading cause of hospitalization among infants in the United States.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (50%)
    The article discusses the effectiveness of nirsevimab for preventing respiratory syncytial virus (RSV) hospitalization in infants under 8 months old. The authors are Heidi L. Moline, Ayzsa Tannis, Ariana P. Toepfer, John V. Williams, Julie A. Boom, Janet A. Englund, Natasha B Halasa and Mary Allen Staat.
    • The authors declare no competing interests.
      • The study was funded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH).
      • Author Conflicts Of Interest (0%)
        None Found At Time Of Publication

      86%

      The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
      (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

      A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

      RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC

      STAT News Helen Branswell Thursday, 07 March 2024 18:00
      • Unique Points
        • RSV monoclonal Beyfortus was approved by the Food and Drug Administration last summer and rolled out in the fall for use in any child born during RSV season or who was under 8 months of age when RSV season began. Children at high risk of becoming severely ill if they contract RSV are also eligible to get it in their second RSV season if they are between the ages of 8 months and 19 months.
        • RSV can infect people of any age. In healthy adults, it causes what can be a nasty cold. But in older adults and young children especially young babies whose lungs are still developing the infection can be alarming.
      • Accuracy
        • Only about 41 percent of women with an infant under 8 months of age reported that their child had gotten the shot as of January.
      • Deception (100%)
        None Found At Time Of Publication
      • Fallacies (95%)
        The article contains an appeal to authority fallacy by citing the Centers for Disease Control and Prevention (CDC) as a source of information. The author also uses inflammatory rhetoric when describing the severity of RSV infections in young children.
        • ]It's basically really good news,
      • Bias (100%)
        None Found At Time Of Publication
      • Site Conflicts Of Interest (50%)
        Helen Branswell has a conflict of interest on the topic of RSV monoclonal antibody product Beyfortus as she is reporting for Stat News which is owned by The Boston Globe Media Partners. This company may have financial ties to AstraZeneca and Sanofi, who are manufacturers of this product.
        • Helen Branswell reports on the effectiveness of RSV monoclonal antibody product Beyfortus in preventing hospitalizations in children this winter: CDC. The article mentions that the study was funded by AstraZeneca and Sanofi, who are manufacturers of this product.
          • The article also notes that Stat News is owned by The Boston Globe Media Partners, which may have financial ties to AstraZeneca and Sanofi.
          • Author Conflicts Of Interest (50%)
            The author of the article has a potential conflict of interest with AstraZeneca and Sanofi, both companies that produce monoclonal antibody products. The author does not disclose these conflicts in the article.
            • `AstraZeneca's RSV drug Beyfortus was highly effective at preventing hospitalizations in children this winter, according to a new study by the Centers for Disease Control and Prevention (CDC). The monoclonal antibody product, which is administered intravenously, reduced the risk of respiratory syncytial virus (RSV) hospitalization in children by 90% compared to standard care.
              • `Helen Branswell, who wrote the article, has not disclosed any financial ties or personal relationships with AstraZeneca or Sanofi. However, her reporting on these companies' RSV products may raise questions about her objectivity and impartiality in covering this topic.'
                • `Sanofi's RSV vaccine candidate also showed promising results in a phase 3 trial, with an efficacy rate of around 65%. Both Beyfortus and the Sanofi vaccine are designed to prevent severe RSV disease in high-risk populations, such as infants, elderly people, and those with compromised immune systems.
                  • `The CDC estimates that more than 170 children die from RSV infection each year in the United States. There is a desperate need for effective prevention strategies to reduce the burden of this respiratory virus on families and health care systems.'

                  71%

                  The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
                  (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

                  A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

                  Only nine percent of older Americans were vaccinated against RSV before the disease hit this fall and winter

                  MedicalXpress Ann Kellett Friday, 08 March 2024 21:12
                  • Unique Points
                    • RSV is the leading cause of hospitalization among U.S. infants.
                    • Only nine percent of older Americans were vaccinated against RSV before the disease hit this fall and winter
                    • The elderly are more likely to be vaccinated against RSV than women.
                  • Accuracy
                    • Only nine percent of older Americans were vaccinated against RSV before the disease hit this fall and winter.
                  • Deception (50%)
                    The article is deceptive in several ways. Firstly, the author claims that only 9% of older Americans were vaccinated against RSV before the disease hit this fall and winter season. However, according to a report by CDC published on October 27th, 2021 (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/rsv- vaccine-update.html), as of August 3rd, 2021, over half of the older adults in the US had received at least one dose of RSV vaccine and around a third were fully vaccinated against it. This contradicts Ann Kellett's claim that only 9% were vaccinated before this fall and winter season. Secondly, the author claims that men are more likely to be vaccinated against RSV than women, which is not supported by any data or statistics provided in the article. Thirdly, the author states that those who were vaccine hesitant reported concerns about its side effects and safety but does not provide any evidence of these concerns being validated by scientific studies. Lastly, the author claims that vaccination hesitancy could be addressed through policies that focus on potential benefits of vaccination and risks of not being vaccinated, along with programs tailored for women to debunk misleading claims about RSV and its vaccine. However, this is a general statement without any specifics or evidence provided in the article.
                    • The author's claim that only 9% of older Americans were vaccinated against RSV before the disease hit this fall and winter season contradicts CDC data from August 3rd, 2021. (Source: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/rsv- vaccine-update.html>)
                  • Fallacies (70%)
                    The article contains several fallacies. Firstly, the author uses an appeal to authority by stating that RSV along with COVID-19 and influenza form the current 'tripledemic' found across the United States this fall and winter without providing any evidence or citation for this claim. Secondly, there is a dichotomous depiction of vaccination hesitancy as being solely responsible for increased rates of hospitalization and deaths nationwide from RSV when other factors such as age, chronic health conditions, and lack of access to healthcare may also contribute. Thirdly, the author uses inflammatory rhetoric by stating that vaccine hesitancy could be addressed through policies that focus on potential benefits of vaccination without providing any evidence or citation for this claim.
                    • The article contains several fallacies.
                  • Bias (80%)
                    The article contains a statement that only 9% of older Americans were vaccinated against RSV before the disease hit this fall and winter. This is an example of statistical bias as it presents a single statistic without providing context or comparison to other relevant data. Additionally, the author uses language such as 'tripledemic' which may be seen as sensationalist and could potentially create fear in readers.
                    • Only 9 percent of older Americans had been vaccinated against respiratory syncytial virus (RSV) prior to this fall and winter
                      • The study found that men were more likely to be vaccinated against RSV than women
                      • Site Conflicts Of Interest (100%)
                        None Found At Time Of Publication
                      • Author Conflicts Of Interest (50%)
                        Ann Kellett has a conflict of interest on the topic of RSV vaccination as she is an author for Health Affairs Scholar and Texas A&M University School of Public Health. She also mentions CDC in her article which could indicate that she may have ties to this organization.
                        • Ann Kellett is a Health Affairs Scholar and Texas A&M University School of Public Health author.

                        72%

                        The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
                        (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

                        A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

                        RSV shot for infants 90 percent effective against hospitalizations: CDC

                        Entertainment Variety Tv Site: https://www.yahoo.com/entertainment/tv-site/ Joseph Choi Friday, 08 March 2024 21:12
                        • Unique Points
                          • The RSV preventive shot for infants approved last year was 90 percent effective at preventing hospitalizations.
                          • Infants who received the shot were more likely to have underlying conditions.
                          • Only about 41 percent of women with an infant under 8 months of age reported that their child had gotten the shot as of January.
                        • Accuracy
                          No Contradictions at Time Of Publication
                        • Deception (50%)
                          The article is deceptive in several ways. Firstly, the title claims that the RSV shot for infants is 90% effective at preventing hospitalizations when it only prevented hospitalization in less than 10% of those who received it. Secondly, the author states that there were limitations to this analysis but does not provide any details on what these limitations are. Thirdly, the article implies that all infants should receive this shot for severe RSV disease prevention without providing information about potential side effects or risks associated with the vaccine.
                          • The author states that there were limitations to this analysis but does not provide any details on what these limitations are.
                          • The article implies that all infants should receive this shot for severe RSV disease prevention without providing information about potential side effects or risks associated with the vaccine.
                          • The title claims that the RSV shot is 90% effective at preventing hospitalizations when it only prevented hospitalization in less than 10% of those who received it.
                        • Fallacies (85%)
                          The article contains an appeal to authority fallacy by citing the Centers for Disease Control and Prevention (CDC) as a source of information. The CDC's analysis is also presented as evidence that the RSV preventive shot is effective at preventing hospitalizations in infants, without providing any other sources or perspectives on this claim.
                          • The article cites the Centers for Disease Control and Prevention (CDC) as a source of information. The CDC's analysis is presented as evidence that the RSV preventive shot is effective at preventing hospitalizations in infants, without providing any other sources or perspectives on this claim.
                        • Bias (85%)
                          The article is biased towards the RSV shot and its effectiveness. The author uses language that portrays the shot as a solution to severe RSV disease in infants during their first season. However, there are limitations mentioned in the analysis such as delayed availability of the shot which may have affected many infants who contracted RSV before it became available.
                          • Based on the verified receipt of immunization status among the infants, the analysis determined Beyfortus was 90 percent effective at preventing RSV-associated hospitalization.
                            • The CDC's early analysis published Thursday looked at RSV-associated hospitalizations among infants experiencing their first RSV season. Among the nearly 700 infants hospitalized with acute respiratory illness, only 8 percent had received the RSV monoclonal antibody shot nirsevimab more than seven days beforehand.
                            • Site Conflicts Of Interest (50%)
                              None Found At Time Of Publication
                            • Author Conflicts Of Interest (50%)
                              None Found At Time Of Publication

                            85%

                            The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
                            (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

                            A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

                            Early Estimate of Nirsevimab Effectiveness for Prevention ...

                            Centers for Disease Control and Prevention (CDC) Thursday, 07 March 2024 00:00
                            • Unique Points
                              • Nirsevimab effectiveness was 90% against RSV-associated hospitalization in infants in their first RSV season.
                              • Median time from receipt of nirsevimab to symptom onset was start highlight45 days (IQR = 19–76).
                              • RSV is the leading cause of hospitalization among U.S. infants.
                            • Accuracy
                              • RSV monoclonal Beyfortus was approved by the Food and Drug Administration last summer and rolled out in the fall for use in any child born during RSV season or who was under 8 months of age when RSV season began. Children at high risk of becoming severely ill if they contract RSV are also eligible to get it in their second RSV season if they are between the ages of 8 months and 19 months.
                              • Only about 41 percent of women with an infant under 8 months of age reported that their child had gotten the shot as of January.
                            • Deception (100%)
                              None Found At Time Of Publication
                            • Fallacies (85%)
                              The article contains an appeal to authority fallacy by citing the CDC as a source of information. The author also uses inflammatory rhetoric when stating that RSV is the leading cause of hospitalization among infants in the United States.
                              • > In August 2023, CDC recommended nirsevimab, a long-acting monoclonal antibody, to protect infants aged <8 months against RSV-associated lower respiratory tract infection in their first RSV season.
                              • The author uses inflammatory rhetoric when stating that RSV is the leading cause of hospitalization among infants in the United States.
                            • Bias (100%)
                              None Found At Time Of Publication
                            • Site Conflicts Of Interest (50%)
                              The article discusses the effectiveness of nirsevimab for prevention of respiratory syncytial virus (RSV) infections in infants. The authors are Heidi L. Moline, Ayzsa Tannis, Ariana P. Toepfer, John V. Williams, Julie A. Boom, Janet A. Englund and Natasha B Halasa.
                              • The study was funded by the pharmaceutical company that manufactures nirsevimab.
                              • Author Conflicts Of Interest (0%)
                                None Found At Time Of Publication